Analysts Set Expectations for Icon Plc’s Q3 2018 Earnings (ICLR)

Icon Plc (NASDAQ:ICLR) – Equities research analysts at Jefferies Group raised their Q3 2018 earnings per share estimates for Icon Plc in a note issued to investors on Monday. Jefferies Group analyst D. Windley now expects that the medical research company will post earnings per share of $1.47 for the quarter, up from their previous estimate of $1.46. Jefferies Group has a “Buy” rating and a $132.00 price target on the stock. Jefferies Group also issued estimates for Icon Plc’s FY2018 earnings at $5.83 EPS and FY2019 earnings at $6.43 EPS.

A number of other analysts have also commented on ICLR. Zacks Investment Research lowered Icon Plc from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. ValuEngine lowered Icon Plc from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. SunTrust Banks, Inc. upgraded Icon Plc from a “hold” rating to a “buy” rating and lifted their price target for the stock from $93.00 to $126.00 in a report on Monday, July 31st. BidaskClub upgraded Icon Plc from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 22nd. Finally, KeyCorp reiterated an “overweight” rating on shares of Icon Plc in a report on Monday, July 31st. Four equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $114.11.

TRADEMARK VIOLATION WARNING: “Analysts Set Expectations for Icon Plc’s Q3 2018 Earnings (ICLR)” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://sportsperspectives.com/2017/10/11/analysts-set-expectations-for-icon-plcs-q3-2018-earnings-iclr.html.

Icon Plc (ICLR) traded up 1.39% on Tuesday, hitting $115.60. The company had a trading volume of 121,638 shares. The stock has a 50 day moving average of $112.41 and a 200-day moving average of $97.57. The stock has a market capitalization of $6.25 billion, a PE ratio of 23.45 and a beta of 0.59. Icon Plc has a one year low of $73.76 and a one year high of $117.53.

Icon Plc (NASDAQ:ICLR) last posted its earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.01. The business had revenue of $431.00 million for the quarter, compared to analyst estimates of $430.68 million. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.14 EPS.

A number of institutional investors have recently modified their holdings of ICLR. Renaissance Technologies LLC raised its stake in shares of Icon Plc by 252.6% in the first quarter. Renaissance Technologies LLC now owns 955,860 shares of the medical research company’s stock valued at $76,201,000 after buying an additional 684,760 shares during the period. Koch Industries Inc. raised its stake in shares of Icon Plc by 17,508.8% in the second quarter. Koch Industries Inc. now owns 666,140 shares of the medical research company’s stock valued at $659,000 after buying an additional 662,357 shares during the period. FMR LLC raised its stake in shares of Icon Plc by 38.4% in the second quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock valued at $224,037,000 after buying an additional 635,950 shares during the period. Clearbridge Investments LLC raised its stake in shares of Icon Plc by 45.2% in the first quarter. Clearbridge Investments LLC now owns 1,594,656 shares of the medical research company’s stock valued at $127,126,000 after buying an additional 496,700 shares during the period. Finally, Janus Henderson Group PLC raised its stake in shares of Icon Plc by 48.4% in the second quarter. Janus Henderson Group PLC now owns 1,068,159 shares of the medical research company’s stock valued at $104,488,000 after buying an additional 348,292 shares during the period. Institutional investors and hedge funds own 91.53% of the company’s stock.

Icon Plc Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History and Estimates for Icon Plc (NASDAQ:ICLR)

Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply